We aimed to investigate whether HER2‐low impacts the prognosis of early‐stage breast cancer overall and in specific subgroups, explore differences in clinicopathologic markers, and examine the role of age in HER2‐low prognostic stratification. The gene discussed is ERBB2; the disease is breast cancer.